The point-of-care fentanyl test kits market is on a strong growth trajectory, with projections indicating an increase from USD 105.4 million in 2023 to over USD 180.9 million by 2033. This growth reflects a compound annual growth rate (CAGR) of 5.5% during the forecast period.
The market for point-of-care fentanyl test kits has been experiencing substantial growth due to several critical factors. The escalating prevalence of fentanyl abuse and the broader opioid crisis are primary drivers behind this surge. Additionally, the increasing demand for immediate and accurate detection of fentanyl in various settings is significantly contributing to the market’s expansion.
Point-of-care fentanyl test kits are vital tools for detecting the presence of fentanyl and its analogs, providing rapid results that are crucial for effective response in both clinical and emergency situations. As the opioid crisis continues to impact communities, the need for reliable and swift testing solutions has become more pronounced.
Governments and regulatory authorities are implementing stricter control measures and regulations to address the fentanyl crisis. These measures emphasize the importance of fentanyl testing, particularly in emergency settings, addiction treatment centers, and law enforcement agencies. The market for point-of-care fentanyl test kits is expected to benefit from these regulatory efforts.
The focus on harm reduction strategies and overdose prevention is increasing globally. Point-of-care fentanyl test kits play a crucial role in these initiatives by enabling individuals to test their substances for the presence of fentanyl and make informed decisions about drug use. The market is expected to benefit from the expanding harm reduction programs and the recognition of the importance of fentanyl testing in reducing overdose risks.
Continued research and development efforts in the field of fentanyl testing are driving technological innovations in point-of-care test kits. Manufacturers are focusing on enhancing the sensitivity, specificity, and ease of use of fentanyl test kits. The market outlook is positive as these advancements lead to the development of more accurate, reliable, and cost-effective test kits.
Key Takeaways from the Point-of-care fentanyl test kits Market:
- The point-of-care fentanyl test kits industry in the United States is predicted to reach US$ 61.8 million by 2033, increasing at a 6.0% CAGR.
- The point-of-care fentanyl test kits industry in the United Kingdom is estimated to reach a market value of US$ 10.0 million, expanding at a CAGR of 6.2% by 2033.
- During the forecast period, the point-of-care fentanyl test kits industry in China is expected to reach a market value of US$ 11.1 million, securing a 5.9% CAGR.
- The point-of-care fentanyl test kits industry in Japan is predicted to reach US$ 8.2 million by 2033, increasing at a 5.8% CAGR.
- During the forecast period, the point-of-care fentanyl test kits industry in South Korea is expected to reach a market share of US$ 6.1 million, securing a 5.6% CAGR.
- With a CAGR of 5.2% from 2023 to 2033, the Drug of Abuse is expected to dominate the point-of-care fentanyl test kits industry.
- With a CAGR of 5.7% from 2023 to 2033, the forensic laboratories is expected to dominate the point-of-care fentanyl test kits industry.
Key Players in the Point-of-Care Fentanyl Test Kits Market Industry
- BTNX Inc.
- Canadian Research Chemicals Inc.
- The Bunk Police
- DanceSafe
- Microgenics Corporation
- NarcCheck
- Opioid Crisis Response Network (OCRN)
- SD Biosensor, Inc.
- Toronto Research Chemicals Inc.
- Wondfo
- Carolina Liquid Chemistries Corp.
A Old Full Report Analysis Click Here
Segmentation Analysis of the Point-of-Care Fentanyl Test Kits Market
By Application:
- Drug of Abuse
- Analgesic Application
By End User:
- Hospitals
- Diagnostics Laboratories
- Forensic Laboratories
- Cancer Research Institutes
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East & Africa
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube